

# PI Worksheet

OMB #: 0925-0753

Expiration Date: 07/31/2021

[Add Note](#)

## STATEMENT OF CONFIDENTIALITY

The purpose of the information collection is to conduct reviews of clinical trial studies. NCI guidelines mandate the participation of institutions in the CIRB for Network group studies. You are being requested to complete this instrument so that we can conduct activities involved with the operations of the NCI CIRB Initiative. Although your participation in Network group research and completion of the forms is voluntary, if you wish to participate in the CIRB, you must complete all questions on the form. The information you provide will be combined for all participants and reported as summaries. It will be kept private to the extent provided by law.

## NOTIFICATION TO RESPONDENT OF ESTIMATED BURDEN

Public reporting burden for this collection of information is estimated to average 20 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0753). Do not return the completed form to this address.

Please refer to the Quickguide on [Completing the Annual Principal Investigator Worksheet](#) for further guidance.

[Add Note](#)

### Reason for submission:

[Add Note](#) [View Audit](#)

(Required)

- First Submission of the Annual Principal Investigator Worksheet About Local Context
- Revised Submission of the Annual Principal Investigator Worksheet About Local Context

## Signatory Institution Information

[Add Note](#) [View Audit](#)

### Submitting User Information

Campbell, Brian

Email: [bcampbell@emmes.com](mailto:bcampbell@emmes.com)

### 1. Enter Principal Investigator email address.

[Add Note](#) [View Audit](#)

(Required)

If the PI's name does not appear above the email address field, this means there is no active account associated with this email address. Please confirm the email address is correct and that it is the email address associated with the PI in IAM. If the email address is correct and the PI name still does not appear, you will need to contact your Signatory Institution's RUMS Update Person and request that this PI be added to the CIRB Roster in RUMS.

[Next](#) [Save for Later](#) [More ▾](#)

### 2. Name of Signatory Institution

[Add Note](#) [View Audit](#)

(Required)

### Calculated Field

[Add Note](#) [View Audit](#)

No answer provided. Campbell, Anne M M.D. \*FIRST SUBMISSION

## Research Staff

[Add Note](#) [View Audit](#)

### 3. How many sub-investigators do you have supporting you in conducting CIRB-approved research?

(Required)

### 4. How many research nurses/CRAs do you have supporting you in conducting CIRB-approved research?

[Add Note](#) [View Audit](#)

(Required)

[Add Note](#) [View Audit](#)

**5. Have you or any of your research staff reported a financial conflict of interest related to any studies on the CIRB menu that resulted in a management plan?**

*(Required)*

Yes  
 No

[Add Note](#) [View Audit](#)

**If Yes, attach the institutionally-approved management plan.**

[Add Note](#)

**NOTE: Principal Investigator Education, Training, and Experience**

*No additional information is required. Information pertaining to investigator education, training, and experience is captured annually through the NCI Investigator Registration.*

[Add Note](#) [View Audit](#)

**Principal Investigator Resources**

**6. How many actively accruing research studies, for which you are the PI, do you have open, including CIRB-approved and those not reviewed by the CIRB?**

*(Required)*

[Add Note](#) [View Audit](#)

**a. CIRB-approved studies by Study ID Number for this PI**

Study-Site	Role	Title	Sponsor
test_Peds-Abington Memorial Hospital-Asplundh Cancer Pavilio	Investigator	testing	
TEST-Abington Memorial Hospital-Asplundh Cancer Pavilio	Investigator	Test	

[Add Note](#) [View Audit](#)

**7. How many study participants are currently receiving study intervention for studies for which you are the PI?**

*(Required)*

[Add Note](#) [View Audit](#)

**Recruitment**

**8. Identify recruitment methods usually used:**

**NOTE: When a protocol includes study-specific recruitment activities, these activities are approved as part of the CIRB's approval of the study and need not be recorded on this worksheet.**

*(Required)*

Network Group/sponsor-supplied handouts  
 Locally developed recruitment materials  
 Other (social media, websites, etc.)  
 None

[Add Note](#) [View Audit](#)

**Please describe.**

**9. Indicate how potential study participants are identified for CIRB-approved studies.**

[Add Note](#) [View Audit](#)

(Required)

- Using recruitment materials as indicated in question 8
- Through usual clinical practice
- Referrals from other providers
- Using a separate IRB-approved screening protocol (reviewed and approved by another IRB)

**Compensation to Study Participants**

[Add Note](#) [View Audit](#)

**10. The CIRB is aware that there is typically no compensation provided for CIRB-studies to study participants for CIRB-approved studies. Describe any compensation/incentives provided by the Signatory Institution or others to study participants enrolled in CIRB-approved studies other than reimbursements that are part of the study, for example: parking validation, cafeteria voucher, other.**

(Required)

**Informed Consent Process**

[Add Note](#)

**Answer the following questions regarding the process used to introduce a trial to a potential study participant and obtain their informed consent.**

**11. Where does the consent discussion take place?**

[Add Note](#) [View Audit](#)

(Required)

**12. Who is authorized to obtain consent?**

[Add Note](#) [View Audit](#)

(Required)

**13. How long does the potential study participant have to review the consent document before a response is required, including time to take the consent document home?**

[Add Note](#) [View Audit](#)

(Required)

**14. Who is available to answer questions?** [Add Note](#) [View Audit](#)

(Required)

**15. How is the potential study participant's understanding of consent assessed?** [Add Note](#) [View Audit](#)

(Required)

**16. How is the informed consent process conducted with non-English speaking potential study participants?** [Add Note](#) [View Audit](#)

(Required)

If short form consent is conducted at your institution, attach a copy of your institution's policy for short form use.

[Add Attachment](#)

**17. Who provides consent?** [Add Note](#) [View Audit](#)

(Required)

- Potential study participant
- Parent for potential pediatric study participant
- Legally Authorized Representative
- Other

*Check all that apply.*

**Please explain.** [Add Note](#) [View Audit](#)

**18. For what languages are translations routinely provided?** [Add Note](#) [View Audit](#)

(Required)

[Add Note](#) [View Audit](#)

**If translations are routinely provided, what process is currently used to translate the informed consent document?**

[Add Note](#) [View Audit](#)

**If applicable, an attachment can be added here.**

[Add Attachment](#)

*Reminder: Translations must be CIRB-approved prior to presenting to a potential study participant.*

[Add Note](#) [View Audit](#)

**19. Describe your institution's policy regarding assent by children and/or impaired adults as applicable.**

**NOTE:** The CIRB makes a determination regarding the requirement for assent and the age determination. Institutions enrolling children must obtain assent from any child in the age range determined by the CIRB. The documentation of the assent is per local policy and should be described here. If a child in the age range determined by the CIRB cannot provide assent, an assent waiver must be requested from the CIRB and obtained prior to enrollment of the child. Consult the [Completing the Assent Waiver Worksheet](#) for further instructions

*(Required)*

[Add Note](#) [View Audit](#)

**If applicable, an attachment can be added here.**

[Add Attachment](#)

[Add Note](#) [View Audit](#)

**20. Describe your institution's process to receive and address concerns from study participants and others about the conduct of the research.**

*(Required)*

[Add Note](#) [View Audit](#)

**Pharmacy Information**

**21. Will the drugs/agents used in the study be managed by a pharmacist?**

*(Required)*

Yes  
 No

[Add Note](#) [View Audit](#)

**If a pharmacist will be managing the drugs/agents used in the study, provide the name and title of the pharmacist at each practice location where research will be conducted.**

[Add Note](#) [View Audit](#)

**If the drugs/agents will not be managed by a pharmacist, provide the name and title of the responsible person for the drugs/agents at each practice/location where research will be conducted.**

[Add Note](#) [View Audit](#)

**22. How is the pharmacist/responsible person provided with a copy of the protocol at each practice location?**

*(Required)*

[Add Note](#)

**Measures to Protect Confidentiality**

**Confidentiality is defined as the study participant's understanding of, and agreement to, the ways identifiable information pertaining to them will be stored and shared. Identifiable information can be printed, electronic, or visual (such as photographs).**

[Add Note](#) [View Audit](#)

**23. Check all measures that will be used to maintain the confidentiality of identifiable information.**

*(Required)*

- Paper-based records will be kept in a secure location and only be accessible to personnel involved in the study.
- Computer-based files will be available to study personnel through the use of access privileges and passwords.
- Prior to obtaining access to identifiable information, study personnel will be required to sign statements agreeing to protect the security and confidentiality of identifiable information.
- Whenever feasible, identifiers will be removed from study-related information.
- Other

[Add Note](#) [View Audit](#)

**Please describe.**

[Add Note](#)

**Measures to Protect Privacy**

**Privacy is defined as the study's participant's ability to control how other people see, touch, or obtain information about them. Violations of privacy can involve circumstances such as being seen without clothing or partially clothed, being photographed without consent, being asked personal questions in a public setting, etc.**

[Add Note](#) [View Audit](#)

**24. Check all measures that will be used to maintain the study participant's privacy.**

*(Required)*

- Use of drapes or other barriers to vision for subjects who are required to disrobe.
- Consent is obtained prior to collecting photographs involving study participants.
- Sensitive information is collected and used with respect to maintaining privacy.
- Individuals are not identified publicly without their consent.
- Other

[Add Note](#) [View Audit](#)

**Please describe.**

## Emergency Resources

[Add Note](#) [View Audit](#)

25. Check all resources available at the site to treat emergencies resulting from study-related procedures.

(Required)

- ACLS trained personnel and crash cart
- BCLS trained personnel
- Emergency response team within facility
- Emergency drugs and supplies to stabilize study participant until emergency personnel arrive
- Staff available to call 911
- Other

Please describe.

[Add Note](#) [View Audit](#)

## Using a Legally Authorized Representative (LAR)

[Add Note](#) [View Audit](#)

26. Do you plan on enrolling study participants through an LAR?

(Required)

- Yes
- No

27. At your institution, describe who may serve as an LAR.

[Add Note](#) [View Audit](#)

If applicable, an attachment can be added here.

[Add Note](#) [View Audit](#)

[Add Attachment](#)

28. Provide a description of how you assess a potential study participant's ability to provide consent.

[Add Note](#) [View Audit](#)

If applicable, an attachment can be added here.

[Add Note](#) [View Audit](#)

[Add Attachment](#)

## Site Reviewer

[Add Note](#) [View Audit](#)

No answer provided.

[Previous](#) [Next](#) [Save for Later](#) [More ▾](#)

## Form Completed

You've completed the form. You can now either save the form for later revision, or submit it.

[Go Back](#) [Save for Later](#) [Print](#) [Submit](#)